Cereno Scientific announces that a sub-study with CS1 within the ongoing Extended Access Program (EAP) now can commence following regulatory approvals. The study will utilise medtech company Fluidda's imaging technology to deepen the understanding of the drug candidate's potential to prevent and reverse pathological remodeling of blood vessels in the lung of patients with the rare disease pulmonary arterial hypertension (PAH). Moreover, company has requested a Type C meeting with the FDA to discuss the next development steps for CS1.